AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
On February 10, 2022, Nasdaq announced that AstraZeneca PLC – ADR (Nasdaq: AZN) will be added to the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index on February 22, 2022. This move follows AstraZeneca's replacement of Xilinx, Inc. (Nasdaq: XLNX) in these indices, indicating a significant shift in the market composition. Investors and analysts may view this inclusion as a reflection of AstraZeneca's growing market relevance.
- AstraZeneca's inclusion in the NASDAQ-100 Index® highlights its market strength.
- Replacement of Xilinx suggests a positive outlook for AstraZeneca among index managers.
- None.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that AstraZeneca PLC – ADR (Nasdaq: AZN), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX) and the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (Nasdaq: XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.
For more information about the company, go to https://www.astrazeneca.com.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
Media Contact
Emily Pan
emily.pan@Nasdaq.com
+1 (646) 637-3964
Issuer & Investor Contact
Index Client Services
Indexservices@Nasdaq.com
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
- NDAQG -
FAQ
What date will AstraZeneca be added to the NASDAQ-100 Index?
Which company is AstraZeneca replacing in the NASDAQ-100 Index?
What is the stock symbol for Nasdaq?
What are the implications of AstraZeneca joining the NASDAQ-100 Index?
